- Home
- LX vs ELVN Comparison
LX vs ELVN Comparison
Compare LX & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LX
- ELVN
- Stock Information
- Founded
- LX 2013
- ELVN 2016
- Country
- LX China
- ELVN United States
- Employees
- LX N/A
- ELVN N/A
- Industry
- LX Finance: Consumer Services
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- LX Finance
- ELVN Health Care
- Exchange
- LX Nasdaq
- ELVN Nasdaq
- Market Cap
- LX 1.1B
- ELVN 1.2B
- IPO Year
- LX 2017
- ELVN 2020
- Fundamental
- Price
- LX $5.70
- ELVN $19.79
- Analyst Decision
- LX
- ELVN Strong Buy
- Analyst Count
- LX 0
- ELVN 5
- Target Price
- LX N/A
- ELVN $41.20
- AVG Volume (30 Days)
- LX 3.2M
- ELVN 421.4K
- Earning Date
- LX 08-07-2025
- ELVN 08-13-2025
- Dividend Yield
- LX 6.62%
- ELVN N/A
- EPS Growth
- LX 86.38
- ELVN N/A
- EPS
- LX 1.28
- ELVN N/A
- Revenue
- LX $1,956,013,429.00
- ELVN N/A
- Revenue This Year
- LX $5.90
- ELVN N/A
- Revenue Next Year
- LX $21.30
- ELVN $25.00
- P/E Ratio
- LX $4.52
- ELVN N/A
- Revenue Growth
- LX 0.80
- ELVN N/A
- 52 Week Low
- LX $1.63
- ELVN $13.30
- 52 Week High
- LX $11.64
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- LX 34.67
- ELVN 47.44
- Support Level
- LX $5.83
- ELVN $18.80
- Resistance Level
- LX $6.23
- ELVN $21.30
- Average True Range (ATR)
- LX 0.22
- ELVN 0.99
- MACD
- LX -0.04
- ELVN -0.06
- Stochastic Oscillator
- LX 2.09
- ELVN 37.00
About LX LexinFintech Holdings Ltd.
LexinFintech Holdings Ltd is an online consumer finance platform and a technology-driven service provider in China. The group is engaged in online direct sales services and online consumer finance services for its customers in the PRC. Geographically, it derives revenue from China.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.